| Home | Generics | Biosimilars | Docs & Positions | Facts & Figures | Press Room | Conferences | Links |
Equivalent generic medicines mean reliable affordable healthcare.About GenericsOverviewAbout the EGAIntroduction Mission Activities Structure Membership Code of Conduct EGA Award Afghanistan Project Milestones Contact EGAThe IGPAAims & MembersWeb Site InfoWhat's New? |
EGA Generic Medicines AwardChallenging ImprovementThe European Generic medicines Association (EGA) established the EGA Generic Medicines Award in 1997 to honour exemplary efforts in research, publications and public awareness in the field of generic medicines. The Added Value of Generic MedicinesFor Continued Development of Generic Medicines When the EGA Award was announced in 1997, the Association’s Board referred to the ongoing debate about the relevancy of generic medicines as compared to newer pharmaceuticals, and particularly about the costs to be borne by society. “It is clear”, the Association said, “that in the interests of cost-containment and public health, the development of generic medicines should be promoted.” Purpose of the EGA Award The EGA Award is intended to stimulate that development and trigger new studies. The twin aspects of such activities — improving the quality of products and of pharmaceutical care — are therefore reflected in the criteria for granting the award. Dual Criteria The EGA Award can presented for achievements in improving pharmaceutical care related to generic medicines. Prime considerations in this instance will be cost-benefit analyses, as they relate not only to patients and health insurers, but to society as a whole. Alternatively, the Award can be granted for research leading to the further development of generic medicines. In this case, results are judged on the basis of the administration, packaging, dosing and application of these medicines. The award may remain vacant for any given year if the jury determines that no suitable candidate has been identified. Nominations and Evaluation Nominations for the award come from member-organizations and EGA affiliates. They are judged by the EGA Executive Committee. Each nomination must be accompanied by the appropriate documentation allowing the formation of a comparative opinion of the contents, quality, therapeutic and socio-economic significance of the candidate's achieven¡ments. The research or study must have been completed within three years preceding its nomination. A nomination must clearly state the value attached by the nominator to the results obtained. All entry reports must be accompanied by a tranlsation into English. For further information about the EGA Award, contact the EGA on EGA Award Winners
|
The EGA Award EGA Award 1998-2000
|
As EGA President Emile Loof noted, “Without the unfailing commitment
of BHF to this project, bringing reliable, affordable medicines to Afghanis
would not have been possible. Their invaluable contribution has truly merited
the EGA Award 2006.”
respective
capacities as EU Commissioners for Enterprise and for Public Health, they met
with health and industry ministers, pharmaceutical leaders and representatives
of patient groups to establish common ground for dialogue and to agree objectives
to improve the competitiveness of the pharmaceutical industry and to meet
Europe’s healthcare goals.
| Copyright © 2004 EGA - European Generic medicines Association • • Cascading Pop-up Menus ©Angus Turnbull |